Adverse myocardial effects of B-vitamin therapy in subjects with chronic kidney disease and hyperhomocysteinaemia

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 9, 2013, Pages 836-842

  Rafeq, Z ^a   Roh, J D ^c,d   Guarino, P ^f   Kaufman, J ^a,e   Joseph, J ^a,b,d,e  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Chronic kidney disease; Diastolic dysfunction; Heart failure; Homocysteine

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN B GROUP;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; END STAGE RENAL DISEASE; FEMALE; HEART FAILURE; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; POST HOC ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSTHORACIC ECHOCARDIOGRAPHY;

CHRONIC KIDNEY DISEASE; DIASTOLIC DYSFUNCTION; HEART FAILURE; HOMOCYSTEINE;

AGED; BODY MASS INDEX; COHORT STUDIES; FOLLOW-UP STUDIES; HEART; HEART FAILURE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MIDDLE AGED; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; SERUM ALBUMIN; VITAMIN B COMPLEX; VITAMINS;

EID: 84884153487     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2012.07.002     Document Type: Article

References (30)

1. McCully K.S. Vascular pathology of hyperhomocysteinemia: implications for the development of arteriosclerosis. Am J Path 1969, 56:111-128.
2. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intake. JAMA 1995, 274:1049-1057.
3. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002, 288:2015-2022. Homocysteine Studies Collaboration.
4. Toole J.F., Malinow M.R., Chambless L.E., Spence J.D., Pettigrew L.C., Howard V.J., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291:565-575.
5. Bonaa K.H., Ueland P.M., Schirmer H., Tverdal A., Steigen T., Wang H., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. NEJM 2006, 354:1578-1588.
6. Lonn E., Yusuf S., Arnold M.J., Sheridan P., Poque J., Micks M. Homocysteine lowering with folic acid and B vitamins in vascular disease. NEJM 2006, 354:1567-1577.
7. Jamison R.L., Hartigan P., Kaufman J.S., Goldfarb D.S., Warren S.R., Guarino P.D., et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease. A randomized controlled trial. JAMA 2007, 298:1163-1170.
8. Joseph J., Washington A., Joseph L., Koehler K., Fink L.M., Hauer-Jenson M., et al. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol 2002, 283:H2567-H2574.
9. Devi S., Kennedy R.H., Joseph L., Shekhawat N.S., Melchert R.B., Joseph J. Effect of long-term hyperhomocysteinemia on myocardial structure and function in hypertensive rats. Cardiovasc Pathol 2006, 15:75-82.
10. Walker E., Black J., Parris C., Bryda E.C., Cansino S., Hunt L., et al. Effect of experimental hyperhomocysteinemia on cardiac structure and function in the rat. Ann Clin Lab Sci 2004, 34:175-180.
11. Sundstrom J., Sullivan L., Selhub J., Benjamin E.J., D'Agostino R.B., Jacques P.F., et al. Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. Eur Heart J 2004, 25:523-530.
12. Blacher J., Demuth K., Guerin A.P., Vadez C., Moatti N., Safar M.E., et al. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 1999, 12:248-255.
13. Maurer M., Burri S., de Marchi S., Hullin R., Martinelli M., Mohacsi P., et al. Plasma homocysteine and cardiovascular risk in heart failure with and without cardiorenal syndrome. Int J Cardiol 2010, 141:32-38.
14. Schofield R.S., Wessel T.R., Walker T.C., Cleeton T.S., Hill J.A., Aranda J.M. Hyperhomocysteinemia in patients with heart failure referred for cardiac transplantation: preliminary observations. Clin Cardiol 2003, 26:407-410.
15. Dhingra R., Gaziano J.M., Djousse L. Chronic kidney disease and the risk of heart failure in men. Circ Heart Fail 2011, 4:138-144.
16. Chae C.U., Albert C.M., Glynn R.J., Guralnik J.M., Curhan G.C. Mild renal insufficiency and risk of congestive heart failure in men and women > or =70 years of age. Am J Cardiol 2003, 92:682-686.
17. Francis M.E., Eggers P.W., Hostetter T.H., Briggs J.P. Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney Int 2004, 66:303-312.
18. Guttormsen A.B., Ueland P.M., Svarstad E., Refsum H. Kinetic basis of hyperhomocyteinemia in patients with chronic renal failure. Kidney Int 1997, 52:495-502.
19. Lin Y.H., Pao K.Y., Wu V.C., Lin Y.L., Chien Y.F., Hung C.S., et al. The influence of estimated creatinine clearance on plasma homocysteine in hypertensive patients with normal serum creatinine. Clin Biochem 2007, 40:230-234.
20. Aksoy N., Aksoy M., Cakmak M., Gergerlioglu H.S., Davutoglu V., Soydinc S., et al. Increased homocysteine in heart failure: a result of renal impairment?. Clin Chem Lab Med 2006, 44:1324-1329.
21. Vasan R.S., Beiser A., D'Agostino R.B., Levy D., Selhub J., Jacques P.F., et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 2003, 289:1251-1257.
22. Okuyan E., Uslu A., Cakar M.A., Sahin I., Onur I., Enhos A., et al. Homocysteine levels in patients with heart failure with preserved ejection fraction. Cardiology 2010, 117:21-27.
23. Tsang T.S., Barnes M.E., Gersh B.J., Bailey K.R., Seward J.B. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 2002, 90:1284-1289.
24. Takemoto Y., Barnes M.E., Seward J.B., Lester S.J., Appleton C.A., Gersh B.J., et al. Usefulness of left atrial volume in predicting first congestive heart failure in patients ≥65 years of age with well-preserved left ventricular systolic function. Am J Cardiol 2005, 96:832-836.
25. van Guldener C., Kulik W., Berger R., Dijkstra D.A., Jakobs C., Reijngoud D.J., et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 1999, 56:1064-1071.
26. Henning B.F., Riezler R., Tepel M., Langer K., Raidt J., Grafe U., et al. Evidence of altered homocysteine metabolism in chronic renal failure. Nephron 1999, 83:314-322.
27. Carrero J.J., Stenvinkel P. Inflammation in end-stage renal disease - what we have learned in 10 years?. Semin Dial 2010, 23:498-509.
28. von Haehling S., Schefold J.C., Lainscak M., Doehner W., Anker S.D. Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin 2009, 5:549-560.
29. Ingrosso D., Cimmino A., Perna A.F., Masella L., De Santo N.G., De Bnois M.L. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet 2003, 361:1693-1699.
30. Miller E.R., Juraschek S., Pastor-Barriuso R., Bazzano L.A., Appel L.J., Guailar E. Meta-analysis of folic acid supplementation trial on risk of cardiovascular interaction with baseline homocysteine levels. Am J Cardiol 2010, 106:517-527.